Literature DB >> 10603138

Conservative treatment for chronic renal failure from birth: a 3-year follow-up study.

M Van Dyck1, N Bilem, W Proesmans.   

Abstract

Fifteen children with chronic renal failure from early infancy who did not require renal replacement therapy were followed for 3 years. Chronic renal failure was defined as a serum creatinine at or above 1 mg/dl for the entire 1st year of life. These patients were treated conservatively with diet and supplements of sodium bicarbonate and sodium chloride, calcium and vitamin D. Erythropoietin was given to 5 patients. Neither nasogastric nor gastrostomy tube feeding was used, and none of the patients received recombinant human growth hormone. We analyzed length, weight, and head circumference at 3, 12, 24, and 36 months of age. All three variables displayed a significant drop in the first 3 months, but remained stable for the whole observation period thereafter. At the age of 3 years, the patients' mean values of length, weight, and head circumference standard deviation score were -1.96, -1.37, and -1.07, respectively. Height velocity during the 1st, 2nd, and 3rd year was 22.2, 10.9, and 7.6 cm per year, respectively. The first two figures and the cumulative height velocity are significantly better than those from a large cohort of chronic renal failure patients collected by the European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood; here the corresponding figures of height velocity were 12.3, 8.3, and 7.6 cm per year. Median serum calcium, phosphate, parathyroid hormone, and albumin levels remained within normal limits for the entire study period. Therapy-resistant hyperparathyroidism occurred in 1 patient and radiological signs of renal osteodystrophy in 4 patients. Kidney length, as measured by ultrasonography, showed almost no growth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10603138     DOI: 10.1007/s004670050717

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

Review 1.  Prognosis of antenatally diagnosed oligohydramnios of renal origin.

Authors:  Markus J Kemper; Dirk E Mueller-Wiefel
Journal:  Eur J Pediatr       Date:  2007-01-05       Impact factor: 3.183

2.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

3.  Growth impairment shows an age-dependent pattern in boys with chronic kidney disease.

Authors:  Miroslav Zivicnjak; Doris Franke; Guido Filler; Dieter Haffner; Kerstin Froede; Richard Nissel; Sanny Haase; Gisela Offner; Jochen H H Ehrich; Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2006-11-28       Impact factor: 3.714

4.  Growth hormone treatment of renal growth failure during infancy and early childhood.

Authors:  Doris Franke; Miroslav Zivicnjak; Jochen H H Ehrich
Journal:  Pediatr Nephrol       Date:  2009-04-15       Impact factor: 3.714

Review 5.  Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective.

Authors:  Richard N Fine
Journal:  Pediatr Nephrol       Date:  2009-12-24       Impact factor: 3.714

Review 6.  Nutrition in children with CRF and on dialysis.

Authors:  Lesley Rees; Vanessa Shaw
Journal:  Pediatr Nephrol       Date:  2007-01-10       Impact factor: 3.714

Review 7.  Growth hormone axis in chronic kidney disease.

Authors:  Shefali Mahesh; Frederick Kaskel
Journal:  Pediatr Nephrol       Date:  2007-08-05       Impact factor: 3.714

Review 8.  Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.

Authors:  Vanessa Shaw; Nonnie Polderman; José Renken-Terhaerdt; Fabio Paglialonga; Michiel Oosterveld; Jetta Tuokkola; Caroline Anderson; An Desloovere; Laurence Greenbaum; Dieter Haffner; Christina Nelms; Leila Qizalbash; Johan Vande Walle; Bradley Warady; Rukshana Shroff; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2019-12-16       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.